Drugs / nangibotide
nangibotide
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03463044 | Apr → Aug 2016 | — | Inotrem | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04429334 | Sep 2020 → May 2022 | COVID-19 | Inotrem | Completed | Met primary |
| Phase 2 | NCT04055909 | Nov 2019 → May 2022 overdue | — | Inotrem | Active not recruiting | Missed primary |
| Phase 2 | NCT03158948 | Jul 2017 → Jun 2018 | — | Inotrem | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nangibotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03158948 ↗ |
| Known as | LR-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297793 ↗ |
| Known as | Motrem | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297793 ↗ |
| Known as | Nangibotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297793 ↗ |
| Action | Inhibit | “through TREM-1 receptor inhibition” PMID 29885068 ↗ Jul 2018 |
| Modality | Peptide | “Formulated LR12 peptide” NCT03158948 ↗ |
| Route | Intravenous | “Nangibotide was administered as a single continuous intravenous infusion.” PMID 29885068 ↗ Jul 2018 |
| Target | TREM1 | “targeting the immunoreceptor TREM-1” PMID 29885068 ↗ Jul 2018 |